Baltimore, Maryland–(Newsfile Corp. – June 7, 2021) – The Board and Management of Flavocure Biotech, Inc. (“Flavocure”) a
BALTIMORE, MARYLAND, August 27, 2020 – For Immediate Release – Flavocure Biotech, Inc. (“Flavocure”) a drug discovery and development
Abstract Pancreatic cancer is particularly refractory to modern therapies, with a 5-year survival rate for patients at a
Baltimore, Maryland–(Newsfile Corp. – June 7, 2021) – The Board and Management of Flavocure Biotech, Inc. (“Flavocure”) a drug discovery
BALTIMORE, MARYLAND, August 27, 2020 – For Immediate Release – Flavocure Biotech, Inc. (“Flavocure”) a drug discovery and development company, announced
Abstract Pancreatic cancer is particularly refractory to modern therapies, with a 5-year survival rate for patients at a dismal 8%.
Flavocure Biotech Inc. aims to be a leader in transforming natural products into new cures for patients.
Get all latest news from Flavocure Biotech
